(function(){
			var content_array=["<p><b>备注<\/b><\/p> \n<p>ADC是一种革命性的靶向癌症治疗方式，旨在将强效药物直接输送到癌细胞，同时避免对健康细胞的伤害。ADC的结构包括单克隆抗体（mAb）和细胞毒性药物，它们通过链接技术组合而成。这些组分的组合方式引导药物仅在癌细胞内释放，以最大化治疗效果并保持药物安全。<\/p> \n<p>到2030年，ADC市场规模预计将超过220亿美元<sup>[1]<\/sup>。<\/p> \n<p>要了解更多关于Lonza的ADC产品，请访问：<a href=\"https:\/\/t.prnasia.com\/t\/aC0LIJGN\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.lonza.com\/biologics\/bioconjugates<\/a><\/p> \n<div> \n <table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\"> \n  <tbody> \n   <tr> \n    <td class=\"prnpr2 prnpl2 prnvab prnsbtb0 prnrbrb0 prnsbbb0 prnsblb0\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\"><sup><span class=\"prnews_span\">[1]<\/span><\/sup><\/span><span class=\"prnews_span\"> <b>Grand View Research<\/b> (May 2023)<\/span><\/p> <\/td> \n   <\/tr> \n  <\/tbody> \n <\/table> \n<\/div> \n<p><b>关于龙沙<\/b><\/p> \n<p>龙沙是全球制药、生物技术与营养市场的优秀合作伙伴。 我们致力于助力客户推出创新药物辅助治疗一系列的疾病，成就更健康的世界。为达成这一使命，我们将先进生产制造、科学专业技术、卓越工艺及技术洞察力完美结合。为满足客户复杂的需求，我们的业务按四大板块划分为生物技术、小分子、细胞与基因、胶囊与健康原料。我们全方位的产品与服务帮助客户在医疗保健行业的发现与创新成果实现商业化。<\/p> \n<p>1897年，龙沙诞生于瑞士的阿尔卑斯山脉地区。发展至今，业务已遍及全球五大洲。我们拥有约17,500名全职员工，由他们组成的高效团队及每一名员工都为我们的业务和所在地区及国家做出意义非凡的改变。2022年，公司销售额达62亿瑞士法郎，核心业务的息税折旧摊销前利润（EBITDA）达20亿瑞士法郎。更多详情，请访问<a href=\"https:\/\/t.prnasia.com\/t\/Uzp6Qwss\" target=\"_blank\" rel=\"nofollow\">www.lonza.com<\/a><\/p> \n<p><b>关于Synaffix<\/b><\/p> \n<p>Synaffix B.V.是一家生物技术公司，利用其基于GlycoConnect™、HydraSpace™和toxSYN™的临床阶段位点特异性ADC技术平台，使ADC产品候选能够实现。通过与Synaffix签订单一许可协议，帮助任何拥有抗体的公司开发出best-in-class ADC产品。<\/p> \n<p>Synaffix平台通过已建立的技术组件的供应链，实现了快速的临床路径。已获得Synaffix技术的许可的技术或其产出物，受专利许可保护的时间至少将持续至2019年。Synaffix的商业模式是针对特定靶点的技术对外授权，例如其已有的与ADC Therapeutics、Mersana Therapeutics、上海美雅珂、信达生物、普方生物、协和麒麟、Genmab、Macrogenics、Emergence Therapeutics、安进、蜂鸟生物科技和Chong Kun Dang Pharma等公司的合作协议。<\/p> \n<p>Synaffix拥有顶级生命科学投资者团队的支持，其中包括Aravis、BioGeneration Ventures、BOM Brabant Ventures和M Ventures。<\/p> \n<p><b>关于Synaffix ADC平台技术<\/b><\/p> \n<p>Synaffix的专有ADC技术平台包括GlycoConnect™、HydraSpace™和toxSYN™技术。这些技术旨在通过显著增强疗效和耐受性，使任何抗体成为best-in-class 的ADC。<\/p> \n<p>GlycoConnect™是一种临床阶段的偶联技术，利用天然抗体糖基进行位点特异性和稳定的药物载荷连接，并可调整为DAR1、DAR2或DAR4格式。HydraSpace™是一种临床阶段的紧凑型高极性间隔技术，旨在进一步提高治疗指数，特别是对于亲水性药物载荷。toxSYN™是一个连接药物载荷平台，涵盖了ADC产品开发的关键、经过验证的作用机制。其中包括强效的拓扑异构酶1抑制剂（SYNtecan E™）、DNA损伤剂（SYNeamicin D™和SYNeamicin G™）、α-微管蛋白（SYNtansine™）和β-微管蛋白（SYNstatin E™和SYNstatin F™）抑制剂，以及通过Synaffix研发团队不断创新努力产生几种尚未发布的专有连接药物载荷。<\/p> \n<p>这三种技术的结合为开发者提供了“一站式”且便捷使用的ADC技术平台，让任何抗体开发者能够开发自己的专有ADC，并让任何ADC开发者能够进一步扩展其项目管线并增强其竞争力。<\/p> \n<p><b>Lonza Contact Details<\/b><\/p> \n<p><b><span class=\"xn-person\">Victoria Morgan<\/span><\/b><br \/>Head of External Communications<br \/>Lonza Group Ltd<br \/>Tel +41 61 316 2283<br \/><a href=\"https:\/\/t.prnasia.com\/t\/o3N4JP7J\" target=\"_blank\" rel=\"nofollow\">victoria.morgan@lonza.com<\/a><\/p> \n<p><b><span class=\"xn-person\">Lyle Wheeler<\/span><\/b><br \/>Investor Relations<br \/>Lonza Group Ltd<br \/>Tel +41 79 154 9522<br \/><a href=\"https:\/\/t.prnasia.com\/t\/eoU8WizI\" target=\"_blank\" rel=\"nofollow\">lyle.wheeler@lonza.com<\/a><\/p> \n<p><b>Synaffix Contact Details<\/b><\/p> \n<p><b>Synaffix B.V.<\/b><br \/><span class=\"xn-person\">Anthony DeBoer<\/span><br \/>Vice President, Business Development<br \/><a href=\"https:\/\/t.prnasia.com\/t\/sOQsShMY\" target=\"_blank\" rel=\"nofollow\">bd@synaffix.com<\/a><\/p> \n<p><b>Optimum Strategic Communications<\/b><br \/><span class=\"xn-person\">Hollie Vile<\/span>, <span class=\"xn-person\">Vici Rabbetts<\/span>, <span class=\"xn-person\">Eleanor Cooper<\/span> <br \/>+ 44 (0) 20 3922 0891<br \/><a href=\"https:\/\/t.prnasia.com\/t\/6cw7NNRv\" target=\"_blank\" rel=\"nofollow\">Synaffix@optimumcomms.com<\/a><\/p> \n<p><b>Additional Information and Disclaimer<\/b><\/p> \n<p>Lonza Group Ltd has its headquarters in <span class=\"xn-location\">Basel, Switzerland<\/span>, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.<\/p> \n<p>Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.<br \/>Privacy Policy <a href=\"https:\/\/t.prnasia.com\/t\/AJepX5dB\" target=\"_blank\" rel=\"nofollow\">link<\/a><\/p> \n<p><a href=\"https:\/\/t.prnasia.com\/t\/fTuBCrbT\" target=\"_blank\" rel=\"nofollow\">To immediately delete all the data<\/a><\/p>"];
			$("#dvExtra").html(content_array[0]);})();